Trials
2 active
11 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)”In the company’s words, NCT05979779 on ClinicalTrials.gov
- Tested for
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver, MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Main trialPhase 2
- “This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).”In the company’s words, NCT05979779 on ClinicalTrials.gov
Other drugs for Non-Alcoholic Fatty Liver Disease
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- ALN-CIDEBRegeneron · Alnylam · Phase 3
- Efimosfermin alfaGSK · Phase 3
- PegozaferminHoffmann-La Roche · 89bio, Inc. · Phase 3
- DR10624Zhejiang Doer Biologics Co., Ltd. · Phase 3
- SemaglutideNovo Nordisk · Phase 3
Coming up1
- Feb 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 21 Jan 2025 | Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis | |
| Phase 2Recruiting | Feb 2027 | A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) | |
| Phase 2Completed | 30 Nov 2021 | Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers | |
| Phase 2Completed | 24 May 2024 | Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF | |
| Phase 2Withdrawn | Feb 2025 | Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes | |
| Phase 1Completed | 30 Mar 2021 | Ascending Dose Study of HU6 in Healthy Volunteers | |
| Phase 1Completed | 30 Apr 2021 | Multiple Ascending Dose Study of HU6 in High BMI Volunteers | |
| Phase 1Completed | 30 Jan 2023 | Safety and Pharmacokinetics of HU6 | |
| Phase 1Completed | 7 May 2024 | A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6 | |
| Phase 1Completed | 15 Nov 2024 | Relative Bioavailability Study of HU6 | |
| Phase 1Completed | 4 Dec 2025 | Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026